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We created an AVLIS facility for the production of primary 
isotope Yb-168 with the enrichment above 20% and with a 
record capacity.  In order to increase the activity and 
improve mechanical properties of ytterbium sources, we 
developed the technology of ytterbium ceramics production. 
The design of new compact source loader with ceramic 
ytterbium sources is now in progress.    
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In proton therapy, as well as in carbon ion therapy, two main 
methods of dose distribution formation can be used: the 
passive particle scattering and the particle scanning in 
several modifications. The pencil-beam scanning is now 
considered as a most advantageous method of dose 
distribution formation. Indeed, this method provides the 
conformance of dose delivery to a tumor of any size with no 
significant dose, delivered to healthy surrounding tissue. 
However, in some cases the beam scanning method may have 
problems. In particular, this is the case of small targets when 
the pencil beam width is comparable with the target size. 
The eye melanoma and small brain metastasis may be 
examples of such small tumors.  
In these cases the application of the old method of passive 
beam scattering with a formation of individual dose 
distributions may be reasonable. However, this method in its 
classical version with a ridge filter, a bolus and a collimator 
is known to fail to provide the sufficiently conformal dose 
distribution with one field: either the maximal dose 
significantly exceeds the tumor volume on its proximate site 
or the dose value changes too much within the tumor 
volume.  
We found a new construction of a two-component ridge filter 
which provides the dose distributions with no mentioned 
above shortcomings (the corresponding patent is pending).  
We have performed a series of calculations with the help of 
the original Monte-Carlo code SRNA in order to find the 
optimal construction of new ridge filters from the point of 
view of dose distribution accuracy and of the device 
manufacturability. In the figure the example of dose 
distribution calculated with the SRNA program is presented. 
As it follows from the figure, even with one field the 95% 
isodose line does not notably leave the tumor volume, 
represented by the black circle. The usual “wings” on 
proximate side of lower isodose lines are absent as well.  The 
experimental tests of these new devices with proton beams 
of the INR linac are now in progress. 
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Purpose: Recently, the interest of using hadron-therapy in 
cancer treatment, particularly for tumors in the vicinity of 
critical organs-at-risk, has grown due to the ability of 
providing high precision dose delivery. In order to fully 
exploit this feature, a precise monitoring of particle beam 
(proton, ions) is mandatory. Therefore, the purpose of our 
project is to develop an online imaging system based on a 
Compton camera to verify the particle beam (proton, ions) 
range by detecting prompt γ rays, induced as a result of 
nuclear reactions between the particle beam and biological 
tissue. 
Material / Methods: The Compton camera consists of two 
main components: a scatterer (tracker), formed by a stack of 
six customized double-sided Si-strip detectors (DSSSD), and a 
monolithic LaBr3 scintillation detector (50x50x30 mm3) acting 
as an absorber detector. The DSSSD detector is processed by 
a compact ASIC based electronics, while the LaBr3 detector is 
read out by a position-sensitive (16x16) multi-anode 
photomultiplier (PMT, Hamamatsu H9500), whose segments 
are processed individually using spectroscopy electronics. 
The energy and timing signals are digitized in a VME-based 
charge-to-digital converter and time-to-digital converter, 
respectively. 
Results: The Compton camera components have been 
characterized in the laboratory using calibration sources. The 
time and energy resolution of the LaBr3 detector were 
measured to be 273 ± 6 ps (FWHM) and 3.5%, using 60Co and 
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137Cs source, respectively. The spatial resolution of this 
detector so far has been determined to be about 5 mm, using 
the k-nearest-neighbour algorithm (k-NN) [1]. 
Moreover, the Compton camera has been commissioned at 
different particle beam facilities. The time-of-flight (TOF) 
capability of the system was evaluated at the Garching 
Tandem accelerator, using a 20 MeV pulsed (400 ns) deuteron 
beam hitting a water phantom, showing prompt γ rays well 
separated from the slower neutrons. The camera was further 
tested with different clinical proton beams from the research 
area of the University Proton Therapy Dresden (100, 160 and 
225 MeV) stopping in either a water or a PMMA phantom, as 
indicated in Fig.1. For all three proton beam energies, the 
analysis of the prompt γ energy versus the TOF showed no 
significant neutron background. The Compton electron 
energy loss was extracted from each DSSSD layer, showing a 
gradual sequential increase of the energy loss from the first 
to the last layer.  
 
 
Figure 1: The Compton camera, enclosed in a Faraday light 
tight cage, is placed under 90o relative to the proton beam 
that hits a water phantom (here at the OncoRay facility, 
Universitäts Protonen Therapie Dresden). 
 
Conclusion: A Compton camera is under development in 
Garching, designed for online ion beam range verification via 
prompt γ detection. The monolithic LaBr3 detector was 
characterized in the laboratory exhibiting excellent energy 
and time resolution as well as a sufficient position resolution. 
The Compton camera was commissioned with a low-energy 
pulsed deuteron beam at the Garching Tandem accelerator 
and with high-energy clinical proton beams at the OncoRay 
facility, Dresden.  
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Purpose: Particle therapy provide a more favorable dose 
distribution compared to x-rays, but limited focus has been 
on the actual biological responses. Effects of carbon ion 
radiation in experimental tumor models has been 
investigated in a limited number of studies, the majority of 
these with tumor growth delay as biological endpoint. To 
elucidate the biological variation in radiation response in 
particle therapy, more in vivo studies are needed. The aim of 
the present study was to compare the biological 
effectiveness of carbon ions relative to x-rays between the 
clinical relevant endpoint tumor control and normal tissue 
damage, both acute and late effects. 
Materials and Methods: CDF1 mice with C3H mouse mammary 
carcinoma placed subcutaneously on the foot of the right 
hind limb were irradiated with single fractions of either 
photons or 12C ions, using a 30-mm spread-out Bragg peak. 
Endpoint of the study was local control (no tumor recurrence 
within 90 days). For the acute skin reaction, non-tumor 
bearing CDF1 mice were irradiated with a comparable 
radiation scheme, and monitored for acute skin damage. Late 
radiation induced fibrosis was measured up to 322 days 
following treatment.  
Results: The TCD50 (dose producing tumor control in 50% of 
mice) values with 95% confidence interval were 29.7 (25.37- 
34.78) Gy for C ions and 43.94 (39.24- 49.2) Gy for photons. 
The corresponding RBE values were 1.48 (1.28-1.72). For 
acute skin damage the MDD50 (dose to produce moist 
desquamation in 50% of mice) values with 95% confidence 
interval were 26.34 (22.99-30.19) Gy for C ions and 35.84 
(32.94-38.98) Gy for photons, resulting in a RBE of 1.36 
(1.20-1.45). For late radiation-induced fibrosis the FD50 (dose 
to produce severe fibrosis in 50% of the mice) with 95% 
confidence interval were 26.5 (23.1 – 30.3) Gy for carbon ions 
and 39.8 (37.8 – 41.8) Gy for photons, with a RBE of 1.50 
(1.33 – 1.69).  
Conclusions: We have established TCD50, MDD50 and FD50 
values for local tumor control and normal tissue damage and 
the corresponding RBE values for carbon ions in a mouse 
model. The observed RBE values were very similar for tumor 
response, acute skin damage and late RIF when irradiated 
with large doses of high- linear energy transfer (LET) carbon 
ions. This study add information to the variation in biological 
effectiveness in different tumor and normal tissue models. 
(Acta Oncologica, In Press) 
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The Proton Therapy Facility at TRIUMF is now in routine 
operation treating ocular tumours using 74 MeV protons 
extracted from the 500 MeV H- cyclotron. In this work, the 
feasibility of using PET scanning for proton dose monitoring is 
investigated. Different lucite phantoms have been irradiated 
with a raw Bragg peak and a spread out Bragg peak of 74 MeV 
and scanned using two PET scanners at UBC hospital. 
Simulation programs GEANT4 and FLUKA are being used to 
validate against experimental measurements. GEANT4 has 
been coupled with EXFOR cross section data of proton 
induced reactions to calculate the axial activity of the 
phantoms. Despite the very simple setup, significant 
discrepancies between the codes have been observed for the 
activity profiles of 11C and 15O and 13N, whereas the beam 
range in lucite has been found to have good agreement.  
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